{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:17:23Z","timestamp":1760235443871,"version":"build-2065373602"},"reference-count":14,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T00:00:00Z","timestamp":1629676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Monoclonal gammopathy of undetermined significance (MGUS) is a highly prevalent condition with the possible risk of progression to multiple myeloma (MM) or a lymphoproliferative neoplasm in a small percentage of patients. Fluorine-18 fluorodeoxyglucose (18F-FDG) positron emission tomography\/computed tomography (PET\/CT) or positron emission tomography\/magnetic resonance imaging (PET\/MRI) are imaging methods increasingly used in patients with MM. The aim of this communication is to underline that, taking into account current evidence-based data, compared to MM the role of 18F-FDG PET\/CT or PET\/MRI in MGUS is still undetermined and more studies should be performed before suggesting 18F-FDG PET\/CT or PET\/MRI for evaluation of MM progression in patients with MGUS.<\/jats:p>","DOI":"10.3390\/medicina57080856","type":"journal-article","created":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T10:24:17Z","timestamp":1629714257000},"page":"856","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The \u201cUndetermined Significance\u201d of 18F-FDG PET\/CT or PET\/MRI in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS)"],"prefix":"10.3390","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9808-780X","authenticated-orcid":false,"given":"Giorgio","family":"Treglia","sequence":"first","affiliation":[{"name":"Clinic of Nuclear Medicine, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland"},{"name":"Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital, 1011 Lausanne, Switzerland"},{"name":"Academic Education, Research and Innovation Area, General Directorate, Ente Ospedaliero Cantonale, 6500 Bellinzona, Switzerland"},{"name":"Faculty of Biology and Medicine, University of Lausanne, 1011 Lausanne, Switzerland"},{"name":"Faculty of Biomedical Sciences, Universit\u00e0 della Svizzera italiana, 6900 Lugano, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Bertagna","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University of Brescia and Spedali Civili Brescia, 25123 Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0810-6494","authenticated-orcid":false,"given":"Domenico","family":"Albano","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University of Brescia and Spedali Civili Brescia, 25123 Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,23]]},"reference":[{"doi-asserted-by":"crossref","unstructured":"Lomas, O.C., Mouhieddine, T.H., Tahri, S., and Ghobrial, I.M. (2020). Monoclonal Gammopathy of Undetermined Significance (MGUS)-Not So Asymptomatic after All. Cancers, 12.","key":"ref_1","DOI":"10.3390\/cancers12061554"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11899-020-00569-2","article-title":"Monoclonal Gammopathy of Undetermined Significance: Current Concepts and Future Prospects","volume":"15","author":"Seth","year":"2020","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1038\/s41375-020-01051-x","article-title":"Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM)","volume":"34","author":"Ho","year":"2020","journal-title":"Leukemia"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"Pawlyn","year":"2021","journal-title":"Lancet"},{"doi-asserted-by":"crossref","unstructured":"Mann, H., Katiyar, V., Varga, C., and Comenzo, R.L. (2021). Smoldering multiple myeloma-Past, present, and future. Blood Rev.","key":"ref_6","DOI":"10.1016\/j.blre.2021.100869"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"101148","DOI":"10.1016\/j.beha.2020.101148","article-title":"Current and potential applications of positron emission tomography for multiple myeloma and plasma cell disorders","volume":"33","author":"Ulaner","year":"2020","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3389\/fmed.2019.00069","article-title":"Interest of Pet Imaging in Multiple Myeloma","volume":"6","author":"Jamet","year":"2019","journal-title":"Front. Med."},{"doi-asserted-by":"crossref","unstructured":"Vicentini, J.R.T., and Bredella, M.A. (2021). Role of FDG PET in the staging of multiple myeloma. Skeletal Radiol.","key":"ref_9","DOI":"10.1007\/s00256-021-03771-2"},{"doi-asserted-by":"crossref","unstructured":"Jamet, B., Bailly, C., Carlier, T., Touzeau, C., Michaud, A.V., Bourgeois, M., Moreau, P., Bodet-Milin, C., and Kraeber-Bodere, F. (2020). Imaging of Monoclonal Gammapathy of Undetermined Significance and Smoldering Multiple Myeloma. Cancers, 12.","key":"ref_10","DOI":"10.3390\/cancers12020486"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","article-title":"International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders","volume":"20","author":"Hillengass","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"939","DOI":"10.4149\/neo_2020_191104N1137","article-title":"Diagnostic relevance of 18F-FDG PET\/CT in newly diagnosed patients with monoclonal gammopathy of undetermined significance (MGUS): Single-center experience","volume":"67","author":"Sandecka","year":"2020","journal-title":"Neoplasma"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40336-019-00314-7","article-title":"Evidence-based indications for the planning of PET or PET\/CT capacities are needed","volume":"7","author":"Fuchs","year":"2019","journal-title":"Clin. Transl. Imaging"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s40336-013-0013-3","article-title":"Meta-analyses and systematic reviews on PET and PET\/CT in oncology: The state of the art","volume":"1","author":"Treglia","year":"2013","journal-title":"Clin. Transl. Imaging"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/57\/8\/856\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:49:39Z","timestamp":1760165379000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/57\/8\/856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,23]]},"references-count":14,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["medicina57080856"],"URL":"https:\/\/doi.org\/10.3390\/medicina57080856","relation":{},"ISSN":["1648-9144"],"issn-type":[{"type":"electronic","value":"1648-9144"}],"subject":[],"published":{"date-parts":[[2021,8,23]]}}}